Goadsby P J, Massiou H, Pascual J, Diener H-C, Dahlöf C G H, Mateos V, Dowson A J, Raets I, Cunha L, Färkkilä M, Manzoni G C
Headache Group, Institute of Neurology, Queen Square, London, UK.
Acta Neurol Scand. 2007 Jan;115(1):34-40. doi: 10.1111/j.1600-0404.2006.00739.x.
To compare almotriptan and zolmitriptan in the treatment of acute migraine.
This multicentre, double-blind trial randomized adult migraineurs to almotriptan 12.5 mg (n = 532) or zolmitriptan 2.5 mg (n = 530) for the treatment of a single migraine attack. The primary end point was sustained pain free plus no adverse events (SNAE); other end points included pain relief and pain free at several time points, sustained pain free, headache recurrence, use of rescue medication, functional impairment, time lost because of migraine, treatment acceptability, and overall treatment satisfaction.
No significant difference was seen in SNAE (almotriptan 29.2% vs zolmitriptan 31.8%) or the other efficacy end points measured. The incidence of triptan-associated AEs and triptan-associated central nervous system AEs was significantly lower for patients receiving almotriptan compared to zolmitriptan.
Almotriptan and zolmitriptan were associated with similar efficacy and overall tolerability in the treatment of acute migraine. Almotriptan was associated with a significantly lower rate of triptan-associated AEs.
比较阿莫曲坦和佐米曲坦治疗急性偏头痛的效果。
这项多中心、双盲试验将成年偏头痛患者随机分为两组，分别服用12.5毫克阿莫曲坦（n = 532）或2.5毫克佐米曲坦（n = 530）来治疗单次偏头痛发作。主要终点是持续无痛且无不良事件（SNAE）；其他终点包括在几个时间点的疼痛缓解和无痛、持续无痛、头痛复发、使用急救药物、功能损害、因偏头痛而损失的时间、治疗可接受性以及总体治疗满意度。
在SNAE方面（阿莫曲坦为29.2%，佐米曲坦为31.8%）或所测量的其他疗效终点方面，未观察到显著差异。与服用佐米曲坦的患者相比，服用阿莫曲坦的患者中曲坦类药物相关不良事件和曲坦类药物相关中枢神经系统不良事件的发生率显著更低。
在治疗急性偏头痛方面，阿莫曲坦和佐米曲坦的疗效和总体耐受性相似。阿莫曲坦与曲坦类药物相关不良事件的发生率显著更低。
